Athersys

Athersys Financing Cash Flow

Delisted·Oct 1, 2026

The Net Financing Cash Flow of Athersys (ATHXQ) as of Nov 20, 2026 is 30.84 M USD. In the previous year, Net Financing Cash Flow was 63.41 M USD — a change of -51.36% (lower).

Financing Cash Flow

30.84 MUSD

YoY

-51.36%

Last updated:

Net Financing Cash Flow of Athersys is 2022 30.84 M USD. Net Financing Cash Flow of Athersys was 2021 63.41 M USD. It decreases by -51.36% lower compared to the previous year.

The Athersys Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2015
10.80 M USD
Jan 1, 2016
3.72 M USD
Jan 1, 2017
38.87 M USD
Jan 1, 2018
36.01 M USD
Jan 1, 2019
19.89 M USD
Jan 1, 2020
79.48 M USD
Jan 1, 2021
63.41 M USD
Jan 1, 2022
30.84 M USD
The Athersys Financing Cash Flow history
YEARFinancing Cash FlowYoY
30.84 MUSD-51.36%
63.41 MUSD-20.22%
79.48 MUSD+299.64%
19.89 MUSD-44.77%
36.01 MUSD-7.36%
38.87 MUSD+944.89%
3.72 MUSD-65.56%
10.80 MUSD-46.72%
20.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Net Financing Cash Flow of Athersys is 30.84 M USD in 2022.

Net Financing Cash Flow of Athersys changed from 63.41 M USD to 30.84 M USD, representing a -51.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Athersys since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys